Development PipelineEnfortumab vedotin

an antibody–drug conjugate being investigated in urothelial carcinoma and other solid tumors

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

EV-302/KEYNOTE-A39: Untreated locally advanced or metastatic urothelial cancer (EV + pembrolizumab vs chemotherapy)

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

KEYNOTE-905/EV-303: MIBC, ineligible for/decline cisplatin (perioperative pembrolizumab ± EV + RC + PLND vs RC + PLND alone)

ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

KEYNOTE-B15/EV-304: Cisplatin-eligible MIBC (perioperative EV + pembrolizumab + RC + PLND vs neoadjuvant chemotherapy + RC + PLND)

ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

EV-103/KEYNOTE-869: Urothelial cancer (EV alone or with other therapies)

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

EV-202: Locally advanced or metastatic malignant solid tumors (EV alone)

ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

EV-104: Non–muscle invasive bladder cancer (intravesical EV alone)

ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

Program Resources

High-level synopsis of enfortumab vedotin and ongoing clinical trials

View/Download

Detailed information about enfortumab vedotin clinical trials

View in Interactive Pipeline